DOCSLIB.ORG

Genetic Factors Influencing Pyrimidine- Antagonist Chemotherapy

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Genetic Factors Influencing Pyrimidine- Antagonist Chemotherapy The Pharmacogenomics Journal (2005) 5, 226–243 & 2005 Nature Publishing Group All rights reserved 1470-269X/05 $30.00 www.nature.com/tpj REVIEW Genetic factors influencing Pyrimidine- antagonist chemotherapy JG Maring1 ABSTRACT 2 Pyrimidine antagonists, for example, 5-fluorouracil (5-FU), cytarabine (ara-C) HJM Groen and gemcitabine (dFdC), are widely used in chemotherapy regimes for 2 FM Wachters colorectal, breast, head and neck, non-small-cell lung cancer, pancreatic DRA Uges3 cancer and leukaemias. Extensive metabolism is a prerequisite for conversion EGE de Vries4 of these pyrimidine prodrugs into active compounds. Interindividual variation in the activity of metabolising enzymes can affect the extent of 1Department of Pharmacy, Diaconessen Hospital prodrug activation and, as a result, act on the efficacy of chemotherapy Meppel & Bethesda Hospital Hoogeveen, Meppel, treatment. Genetic factors at least partly explain interindividual variation in 2 The Netherlands; Department of Pulmonary antitumour efficacy and toxicity of pyrimidine antagonists. In this review, Diseases, University of Groningen & University Medical Center Groningen, Groningen, The proteins relevant for the efficacy and toxicity of pyrimidine antagonists will Netherlands; 3Department of Pharmacy, be summarised. In addition, the role of germline polymorphisms, tumour- University of Groningen & University Medical specific somatic mutations and protein expression levels in the metabolic Center Groningen, Groningen, The Netherlands; pathways and clinical pharmacology of these drugs are described. Germline 4Department of Medical Oncology, University of Groningen & University Medical Center polymorphisms of uridine monophosphate kinase (UMPK), orotate phos- Groningen, Groningen, The Netherlands phoribosyl transferase (OPRT), thymidylate synthase (TS), dihydropyrimidine dehydrogenase (DPD) and methylene tetrahydrofolate reductase (MTHFR) Correspondence: and gene expression levels of OPRT, UMPK, TS, DPD, uridine phosphorylase, Dr JG Maring, Department of Pharmacy, uridine kinase, thymidine phosphorylase, thymidine kinase, deoxyuridine Diaconessen Hospital Meppel & Bethesda Hospital Hoogeveen, Hoogeveenseweg 38, triphosphate nucleotide hydrolase are discussed in relation to 5-FU efficacy. 7943KA Meppel, The Netherlands. Cytidine deaminase (CDD) and 50-nucleotidase (5NT) gene polymorphisms Tel: þ 31 522 234900 and CDD, 5NT, deoxycytidine kinase and MRP5 gene expression levels and Fax: þ 31 522 243900 their potential relation to dFdC and ara-C cytotoxicity are reviewed. E-mail: [email protected] The Pharmacogenomics Journal (2005) 5, 226–243. doi:10.1038/sj.tpj.6500320 Keywords: pyrimidine antagonists; 5-fluorouracil; gemcitabine; cytarabine; poly- morphisms; mutations; gene expression INTRODUCTION Pyrimidine antagonists belong to the group of antimetabolite anticancer drugs and show structural resemblance with naturally occurring nucleotides (see Figure 1). Their action is accomplished through incorporation as false precursor in DNA or RNA or through inhibition of proteins involved in nucleotide metabolism. The most commonly used pyrimidine antagonists are 5-fluorouracil (5-FU), gemcitabine (dFdC) and cytarabine (ara-C). Newer oral variants of 5-FU are capecitabine and tegafur. 5-FU and its analogues are used, for example, in the treatment of colorectal, breast and head and neck cancer,1–3 whereas dFdC is especially prescribed for non-small-cell lung cancer and pancreatic cancer.4,5 Ara- C is used in the treatment of leukaemia.6 All pyrimidine antagonists are prodrugs Received: 17 December 2004 Revised: 3 May 2005 and intracellular conversion into cytotoxic nucleosides and nucleotides is Accepted: 5 May 2005 needed to produce cytotoxic metabolites. Proteins, involved in pyrimidine Pyrimidine antagonist pharmacogenetics JG Maring et al 227 Figure 1 Overview of the chemical structures of the naturally occurring pyrimidines cytosine and uracil and the synthetic pyrimidine analogues cytarabine, dFdC, capecitabine, 5-Fu and tegafur. metabolism, handle these synthetic drugs, as if they were activity results from inhibition of thymidylate synthase (TS) naturally occurring substrates. The extensive metabolism of by FdUMP, as well as from incorporation of 5-FU metabolites pyrimidine antagonists implies that the intracellular con- into RNA and DNA. Only a small part of the 5-FU dose is centrations of cytotoxic metabolites, thus indirectly the activated via these routes, as in humans 80–90% of the potential antitumour effects, largely depend on intracellular administered dose is degraded to 5,6 dihydrofluorouracil metabolic enzyme activity. (DHFU) by dihydropyrimidine dehydrogenase (DPD). DHFU The aim of this review is to summarise pharmacogenomic can be further degraded to fluoro-b-ureidopropionate data regarding proteins related to the efficacy and toxicity of (FUPA) by dihydropyrimidinase (DPYS) and subsequently pyrimidine antagonists and to identify potential predictive to fluoro-b-alanine (FBAL) by b-ureidopropionase (BUP1). 5- and/or prognostic genetic factors for toxicity and treatment FU degradation occurs in all tissues, including tumour outcome. The impact of germline polymorphisms as well as tissue, but is highest in the liver.9 tumour-specific somatic mutations and protein expression levels on the clinical pharmacology and metabolic pathways of these drugs will be discussed. Capecitabine and tegafur Capecitabine is an oral prodrug of 5-FU. After absorption Metabolic Pathways of Pyrimidine Antagonists from the gut, capecitabine is converted into 50-deoxy-5- 5-Fluorouracil fluorocytidine (50-dFCR) by carboxyl-esterase in the liver, The anabolic conversion of 5-FU into nucleotides is essential and subsequently further converted into 50-deoxy-5-fluoro- for its action. Several enzymes of the pyrimidine metabolic uridine (50-dFUR) by cytidine deaminase (CDD). Finally, 5- pathway are required for the conversion of 5-FU to FU results from bioconversion of 50-dFUR by TP10 (see Figure nucleotides.7 Cytotoxic nucleotides can be formed by three 2). Tegafur is another oral 5-FU prodrug, that is converted routes, as illustrated in Figure 2: (1) conversion of 5-FU to 5- into 5-FU by cytochrome P450 (CYP450) enzymes in the fluoro-uridine-monophosphate (FUMP) by orotate phos- liver. CYP2A6 is the main CYP450 enzyme involved in phoribosyl transferase (OPRT); (2) sequential conversion of tegafur activation, but CYP1A2 and CYP2C8 also play a role 5-FU to FUMP by uridine phosphorylase (UP) and uridine (see Figure 2). Tegafur is combined with uracil in a molar kinase; (3) sequential conversion of 5-FU to 5-fluoro-deoxy- proportion of 1 : 4 available in the commercial preparation uridine-monophosphate (FdUMP) by thymidine phospho- UFTs. Uracil is a competitive substrate for DPD and its role rylase (TP) and thymidine kinase (TK).8 The antitumour in UFTs is to diminish 5-FU catabolism by DPD. www.nature.com/tpj Pyrimidine antagonist pharmacogenetics JG Maring et al 228 Figure 2 Metabolism of 5-FU and 5-FU analogues. For explanation of symbols and metabolic routes, see text. dFdC and ara-C ara-C, which halts polymerase progression at the analogue insertion site. The masked termination of dFdC makes the The metabolic pathways of dFdC and ara-C are almost inserted analogue more resistant to removal from DNA.12 alike11,12 (see Figure 3). Membrane transport of both dFdC Other differences with ara-C are the faster membrane and ara-C is mediated by equilibrative nucleoside transpor- transport velocity of dFdC, the greater effectiveness of dFdC ters. Subsequently, dFdC is phosphorylated into dFdC phosphorylation by dCK and the longer intracellular monophosphate (dFdCMP) by deoxycytidine kinase (dCK). retention of dFdCTP. These factors may, at least in part, The same enzyme is responsible for the intracellular explain the different spectra of antitumour activity of both phosphorylation of ara-C into cytarabine monophosphate drugs. Only a small part of the dFdC and ara-C dose is (ara-CMP). dCK is the rate-limiting enzyme in the biotrans- responsible for the cytotoxic effects, since more than 90% of formation of both dFdC and ara-C. Inactivation of dFdCMP the dose is inactivated by the enzyme CDD into dFdU and and ara-CMP can occur through dephosphorylation by 50- uracil-arabinoside (ara-U), respectively. nucleotidase (5NT). Monophosphates, escaping from de- phosphorylation are available for further phosphorylation Germline Polymorphisms and Fluoropyrimidine Efficacy into di- and triphospates by dCMP kinase and nucleoside 5-Fluorouracil diphosphate kinase, respectively. dFdC diphosphate (dFdCDP) is a potent inhibitor of the enzyme ribonucleotide Genetic polymorphisms of enzymes involved in the meta- reductase (RNR), which will lead to depletion of deoxycy- bolic activation pathway of 5-FU have been described for the tidine diphosphate (dCDP) and deoxycytidine triphosphate enzymes uridine monophosphate kinase (UMPK) and (dCTP) in the cell. This may favour the incorporation of orotate phosphorylase transferase (OPRT). Three allelic dFdCTP into DNA. Moreover, dFdC has the unique property variants of UMPK have been recognised in the human that, after incorporation of dFdC monophosphate in DNA, population: UMPK1, UMPK2 and UMPK3.14 The UMPK1 one more deoxynucleotide molecule can be inserted. This allele is associated with about three times the catalytic stops DNA polymerase.13 This pattern is distinct from that of activity of the UMPK2 allele. Therefore, UMPK2 homo- The Pharmacogenomics Journal
Load more

Recommended publications
  • Journal of Biotechnology 193 (2015) 37–40
    Journal of Biotechnology 193 (2015) 37–40 Contents lists available at ScienceDirect Journal of Biotechnology j ournal homepage: www.elsevier.com/locate/jbiotec Short communication Blockage of the pyrimidine biosynthetic pathway affects riboflavin production in Ashbya gossypii 1 1 ∗ Rui Silva , Tatiana Q. Aguiar , Lucília Domingues CEB – Centre of Biological Engineering, University of Minho, 4710-057 Braga, Portugal a r t i c l e i n f o a b s t r a c t Article history: The Ashbya gossypii riboflavin biosynthetic pathway and its connection with the purine pathway have Received 10 September 2014 been well studied. However, the outcome of genetic alterations in the pyrimidine pathway on riboflavin Received in revised form 6 November 2014 production by A. gossypii had not yet been assessed. Here, we report that the blockage of the de novo Accepted 7 November 2014 pyrimidine biosynthetic pathway in the recently generated A. gossypii Agura3 uridine/uracil auxotrophic Available online 15 November 2014 strain led to improved riboflavin production on standard agar-solidified complex medium. When extra uridine/uracil was supplied, the production of riboflavin by this auxotroph was repressed. High concen- Keywords: trations of uracil hampered this (and the parent) strain growth, whereas excess uridine favored the A. Ashbya gossypii gossypii Agura3 growth. Considering that the riboflavin and the pyrimidine pathways share the same Pyrimidine pathway precursors and that riboflavin overproduction may be triggered by nutritional stress, we suggest that Riboflavin production Uridine/uracil auxotrophy overproduction of riboflavin by the A. gossypii Agura3 may occur as an outcome of a nutritional stress Nutritional stress response and/or of an increased availability in precursors for riboflavin biosynthesis, due to their reduced consumption by the pyrimidine pathway.
    [Show full text]
  • Folic Acid Antagonists: Antimicrobial and Immunomodulating Mechanisms and Applications
    International Journal of Molecular Sciences Review Folic Acid Antagonists: Antimicrobial and Immunomodulating Mechanisms and Applications Daniel Fernández-Villa 1, Maria Rosa Aguilar 1,2 and Luis Rojo 1,2,* 1 Instituto de Ciencia y Tecnología de Polímeros, Consejo Superior de Investigaciones Científicas, CSIC, 28006 Madrid, Spain; [email protected] (D.F.-V.); [email protected] (M.R.A.) 2 Consorcio Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina, 28029 Madrid, Spain * Correspondence: [email protected]; Tel.: +34-915-622-900 Received: 18 September 2019; Accepted: 7 October 2019; Published: 9 October 2019 Abstract: Bacterial, protozoan and other microbial infections share an accelerated metabolic rate. In order to ensure a proper functioning of cell replication and proteins and nucleic acids synthesis processes, folate metabolism rate is also increased in these cases. For this reason, folic acid antagonists have been used since their discovery to treat different kinds of microbial infections, taking advantage of this metabolic difference when compared with human cells. However, resistances to these compounds have emerged since then and only combined therapies are currently used in clinic. In addition, some of these compounds have been found to have an immunomodulatory behavior that allows clinicians using them as anti-inflammatory or immunosuppressive drugs. Therefore, the aim of this review is to provide an updated state-of-the-art on the use of antifolates as antibacterial and immunomodulating agents in the clinical setting, as well as to present their action mechanisms and currently investigated biomedical applications. Keywords: folic acid antagonists; antifolates; antibiotics; antibacterials; immunomodulation; sulfonamides; antimalarial 1.
    [Show full text]
  • SYN-40585 SYNRIBO Digital PI, Pil and IFU 5/2021 V3.Indd
    SYN-40585 CONTRAINDICATIONS HIGHLIGHTS OF PRESCRIBING INFORMATION None. These highlights do not include all the information needed to use SYNRIBO safely and WARNINGS AND PRECAUTIONS effectively. See full prescribing information for SYNRIBO. • Myelosuppression: Severe and fatal thrombocytopenia, neutropenia and anemia. Monitor SYNRIBO® (omacetaxine mepesuccinate) for injection, for subcutaneous use hematologic parameters frequently (2.3, 5.1). Initial U.S. Approval: 2012 • Bleeding: Severe thrombocytopenia and increased risk of hemorrhage. Fatal cerebral hemorrhage and severe, non-fatal gastrointestinal hemorrhage (5.1, 5.2). INDICATIONS AND USAGE Hyperglycemia: Glucose intolerance and hyperglycemia including hyperosmolar non-ketotic SYNRIBO for Injection is indicated for the treatment of adult patients with chronic or accelerated • hyperglycemia (5.3). phase chronic myeloid leukemia (CML) with resistance and/or intolerance to two or more Embryo-Fetal Toxicity: Can cause fetal harm. Advise females of reproductive potential of the tyrosine kinase inhibitors (TKI) (1). • potential risk to a fetus and to use an effective method of contraception (5.4, 8.1, 8.3). DOSAGE AND ADMINISTRATION ADVERSE REACTIONS Induction Dose: 1.25 mg/m2 administered by subcutaneous injection twice daily for • Most common adverse reactions (frequency ≥ 20%): thrombocytopenia, anemia, neutropenia, 14 consecutive days of a 28-day cycle (2.1). diarrhea, nausea, fatigue, asthenia, injection site reaction, pyrexia, infection, and lymphopenia Maintenance Dose: 1.25 mg/m2 administered by subcutaneous injection twice daily for • (6.1). 7 consecutive days of a 28-day cycle (2.2). • Dose modifications are needed for toxicity (2.3). To report SUSPECTED ADVERSE REACTIONS, contact Teva Pharmaceuticals at 1-888-483-8279 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
    [Show full text]
  • WHO Drug Information Vol
    WHO Drug Information Vol. 31, No. 3, 2017 WHO Drug Information Contents Medicines regulation 420 Post-market monitoring EMA platform gains trade mark; Automated 387 Regulatory systems in India FDA field alert reports 421 GMP compliance Indian manufacturers to submit self- WHO prequalification certification 421 Collaboration 402 Prequalification process quality China Food and Drug Administration improvement initiatives: 2010–2016 joins ICH; U.S.-EU cooperation in inspections; IGDRP, IPRF initiatives to join 422 Medicines labels Safety news Improved labelling in Australia 423 Under discussion 409 Safety warnings 425 Approved Brimonidine gel ; Lactose-containing L-glutamine ; Betrixaban ; C1 esterase injectable methylprednisolone inhibitor (human) ; Meropenem and ; Amoxicillin; Azithromycin ; Fluconazole, vaborbactam ; Delafloxacin ; Glecaprevir fosfluconazole ; DAAs and warfarin and pibrentasvir ; Sofosbuvir, velpatasvir ; Bendamustine ; Nivolumab ; Nivolumab, and voxilaprevir ; Cladribine ; Daunorubicin pembrolizumab ; Atezolizumab ; Ibrutinib and cytarabine ; Gemtuzumab ozogamicin ; Daclizumab ; Loxoprofen topical ; Enasidenib ; Neratinib ; Tivozanib ; preparations ; Denosumab ; Gabapentin Guselkumab ; Benznidazole ; Ciclosporin ; Hydroxocobalamine antidote kit paediatric eye drops ; Lutetium oxodotreotide 414 Diagnostics Gene cell therapy Hightop HIV home testing kits Tisagenlecleucel 414 Known risks Biosimilars Warfarin ; Local corticosteroids Bevacizumab; Adalimumab ; Hydroquinone skin lighteners Early access 415 Review outcomes Idebenone
    [Show full text]
  • A Phase II Study of Paclitaxel and Capecitabine As a First-Line Combination Chemotherapy for Advanced Gastric Cancer
    British Journal of Cancer (2008) 98, 316 – 322 & 2008 Cancer Research UK All rights reserved 0007 – 0920/08 $30.00 www.bjcancer.com A phase II study of paclitaxel and capecitabine as a first-line combination chemotherapy for advanced gastric cancer Clinical Studies HJ Kang1, HM Chang1, TW Kim1, M-H Ryu1, H-J Sohn1, JH Yook2,STOh2, BS Kim2, J-S Lee1 and Y-K Kang*,1 1 2 Division of Oncology, Department of Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea; Department of Surgery, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea Paclitaxel and capecitabine, which have distinct mechanisms of action and toxicity profiles, have each shown high activity as single agents in gastric cancer. Synergistic interaction between these two drugs was suggested by taxane-induced upregulation of thymidine phosphorylase. We, therefore, evaluated the antitumour activity and toxicities of paclitaxel and capecitabine as first-line therapy in patients with advanced gastric cancer (AGC). Patients with histologically confirmed unresectable or metastatic AGC were treated À2 À2 with capecitabine 825 mg m p.o. twice daily on days 1–14 and paclitaxel 175 mg m i.v. on day 1 every 3 weeks until disease progression or unacceptable toxicities. Between June 2002 and May 2004, 45 patients, of median age 57 years (range ¼ 38–73 years), were treated with the combination of capecitabine and paclitaxel. After a median 6 cycles (range ¼ 1–9 cycles) of chemotherapy, 43 were evaluable for toxicity and response. A total of 2 patients showed complete response and 20 showed partial response making the overall response rate 48.9% (95% CI ¼ 30.3–63.5%).
    [Show full text]
  • A Phase II Study of Capecitabine and Docetaxel Combination Chemotherapy in Patients with Advanced Gastric Cancer
    British Journal of Cancer (2004) 90, 1329 – 1333 & 2004 Cancer Research UK All rights reserved 0007 – 0920/04 $25.00 www.bjcancer.com A phase II study of capecitabine and docetaxel combination chemotherapy in patients with advanced gastric cancer YH Park*,1, B-Y Ryoo1, S-J Choi1and H-T Kim1 1 Division of Haematology and Oncology, Department of Internal Medicine, Korea Institute of Radiological and Medical Science, Seoul, Korea Clinical Capecitabine and docetaxel have considerable single-agent activity in gastric cancer with distinct mechanisms of action and no overlap of key toxicities. A synergistic interaction between these two drugs is mediated by taxane-induced upregulation of thymidine phosphorylase. We investigated the activity and the feasibility of capecitabine and docetaxel combination chemotherapy in patients with previously untreated advanced gastric cancer (AGC). From September 2001 to March 2003, 42 patients with AGC received À2 À2 21-day cycles of oral capecitabine (1250 mg m twice daily on days 1–14) and docetaxel (75 mg m i.v. on day 1). The patients received a total of 164 cycles of chemotherapy. The median age was 53.5 years (range 33–73 years). The overall response rate in the 38 efficacy-evaluable patients was 60% (95% confidence interval, 45–74%). The median progression-free survival was 5.2 months (range, 1.0–15.5 þ months) and the median overall survival was 10.5 months (range, 2.9–23.7 þ months). The most common grade 3/4 adverse events were hand–foot syndrome (HFS: G3 50%), neutropenia (15%) and leucopenia (12%). Further studies of this combination are clearly warranted, albeit with lower doses of both agents (1000 mg mÀ2 twice daily and 60 mg mÀ2) to reduce the rate of HFS and onycholysis.
    [Show full text]
  • The Regulation of Carbamoyl Phosphate Synthetase-Aspartate Transcarbamoylase-Dihydroorotase (Cad) by Phosphorylation and Protein-Protein Interactions
    THE REGULATION OF CARBAMOYL PHOSPHATE SYNTHETASE-ASPARTATE TRANSCARBAMOYLASE-DIHYDROOROTASE (CAD) BY PHOSPHORYLATION AND PROTEIN-PROTEIN INTERACTIONS Eric M. Wauson A dissertation submitted to the faculty of the University of North Carolina at Chapel Hill in partial fulfillment of the requirements for the degree of Doctor of Philosophy in the Department of Pharmacology. Chapel Hill 2007 Approved by: Lee M. Graves, Ph.D. T. Kendall Harden, Ph.D. Gary L. Johnson, Ph.D. Aziz Sancar M.D., Ph.D. Beverly S. Mitchell, M.D. 2007 Eric M. Wauson ALL RIGHTS RESERVED ii ABSTRACT Eric M. Wauson: The Regulation of Carbamoyl Phosphate Synthetase-Aspartate Transcarbamoylase-Dihydroorotase (CAD) by Phosphorylation and Protein-Protein Interactions (Under the direction of Lee M. Graves, Ph.D.) Pyrimidines have many important roles in cellular physiology, as they are used in the formation of DNA, RNA, phospholipids, and pyrimidine sugars. The first rate- limiting step in the de novo pyrimidine synthesis pathway is catalyzed by the carbamoyl phosphate synthetase II (CPSase II) part of the multienzymatic complex Carbamoyl phosphate synthetase, Aspartate transcarbamoylase, Dihydroorotase (CAD). CAD gene induction is highly correlated to cell proliferation. Additionally, CAD is allosterically inhibited or activated by uridine triphosphate (UTP) or phosphoribosyl pyrophosphate (PRPP), respectively. The phosphorylation of CAD by PKA and ERK has been reported to modulate the response of CAD to allosteric modulators. While there has been much speculation on the identity of CAD phosphorylation sites, no definitive identification of in vivo CAD phosphorylation sites has been performed. Therefore, we sought to determine the specific CAD residues phosphorylated by ERK and PKA in intact cells.
    [Show full text]
  • Sequence Variation in the Dihydrofolate Reductase-Thymidylate Synthase (DHFR-TS) and Trypanothione Reductase (TR) Genes of Trypanosoma Cruzi
    Molecular & Biochemical Parasitology 121 (2002) 33Á/47 www.parasitology-online.com Sequence variation in the dihydrofolate reductase-thymidylate synthase (DHFR-TS) and trypanothione reductase (TR) genes of Trypanosoma cruzi Carlos A. Machado *, Francisco J. Ayala Department of Ecology and Evolutionary Biology, University of California, Irvine, CA 92697-2525, USA Received 15 November 2001; received in revised form 25 January 2002 Abstract Dihydrofolate reductase-thymidylate synthase (DHFR-TS) and trypanothione reductase (TR) are important enzymes for the metabolism of protozoan parasites from the family Trypanosomatidae (e.g. Trypanosoma spp., Leishmania spp.) that are targets of current drug-design studies. Very limited information exists on the levels of genetic polymorphism of these enzymes in natural populations of any trypanosomatid parasite. We present results of a survey of nucleotide variation in the genes coding for those enzymes in a large sample of strains from Trypanosoma cruzi, the agent of Chagas’ disease. We discuss the results from an evolutionary perspective. A sample of 31 strains show 39 silent and five amino acid polymorphisms in DHFR-TS, and 35 silent and 11 amino acid polymorphisms in TR. No amino acid replacements occur in regions that are important for the enzymatic activity of these proteins, but some polymorphisms occur in sites previously assumed to be invariant. The sequences from both genes cluster in four major groups, a result that is not fully consistent with the current classification of T. cruzi in two major groups of strains. Most polymorphisms correspond to fixed differences among the four sequence groups. Two tests of neutrality show that there is no evidence of adaptivedivergence or of selectiveevents having shaped the distribution of polymorphisms and fixed differences in these genes in T.
    [Show full text]
  • Metabolism of Purines and Pyrimidines in Health and Disease
    39th Meeting of the Polish Biochemical Society Gdañsk 16–20 September 2003 SESSION 6 Metabolism of purines and pyrimidines in health and disease Organized by A. C. Sk³adanowski, A. Guranowski 182 Session 6. Metabolism of purines and pyrimidines in health and disease 2003 323 Lecture The role of DNA methylation in cytotoxicity mechanism of adenosine analogues in treatment of leukemia Krystyna Fabianowska-Majewska Zak³ad Chemii Medycznej IFiB, Uniwersytet Medyczny, ul. Mazowiecka 6/8, 92 215 £ódŸ Changes in DNA methylation have been recognized tory effects of cladribine and fludarabine on DNA as one of the most common molecular alterations in hu- methylation, after 48 hr growth of K562 cells with the man neoplastic diseases and hypermethylation of drugs, are non-random and affect mainly CpG rich is- gene-promoter regions is one of the most frequent lands or CCGG sequences but do not affect sepa- mechanisms of the loss of gene functions. For this rea- rately-located CpG sequences. The analysis showed son, DNA methylation may be a tool for detection of that cladribine (0.1 mM) reduced the methylated early cell transformations as well as predisposition to cytosines in CpG islands and CCGG sequences to a sim- metastasis process. Moreover, DNA methylation seems ilar degree. The inhibition of cytosine methylation by to be a promissing target for new preventive and thera- fludarabine (3 mM) was observed mainly in CCGG se- peutic strategies. quences, sensitive to HpaII, but the decline in the meth- Our studies on DNA methylation and cytotoxicity ylated cytosine, located in CpG island was 2-fold lower mechanism of antileukemic drugs, cladribine and than that with cladribine.
    [Show full text]
  • A Proteomic Approach to Uncover Neuroprotective Mechanisms of Oleocanthal Against Oxidative Stress
    International Journal of Molecular Sciences Article A Proteomic Approach to Uncover Neuroprotective Mechanisms of Oleocanthal against Oxidative Stress Laura Giusti 1,†, Cristina Angeloni 2,†, Maria Cristina Barbalace 3, Serena Lacerenza 4, Federica Ciregia 5, Maurizio Ronci 6 ID , Andrea Urbani 7, Clementina Manera 4, Maria Digiacomo 4 ID , Marco Macchia 4, Maria Rosa Mazzoni 4, Antonio Lucacchini 1 ID and Silvana Hrelia 3,* ID 1 Department of Clinical and Experimental Medicine, University of Pisa, 56126 Pisa, Italy; [email protected] (L.G.); [email protected] (A.L.) 2 School of Pharmacy, University of Camerino, 62032 Camerino, Italy; [email protected] 3 Department for Life Quality Studies, Alma Mater Studiorum, University of Bologna, 47921 Rimini, Italy; [email protected] 4 Department of Pharmacy, University of Pisa, 56126 Pisa, Italy; [email protected] (S.L.); [email protected] (C.M.); [email protected] (M.D.); [email protected] (M.M.); [email protected] (M.R.M.) 5 Department of Rheumatology, GIGA Research, Centre Hospitalier Universitaire (CHU) de Liège, University of Liège, 4000 Liège, Belgium; [email protected] 6 Department of Medical, Oral and Biotechnological Sciences, University G. d’Annunzio of Chieti-Pescara, 65127 Pescara, Italy; [email protected] 7 Institute of Biochemistry and Clinical Biochemistry, Catholic University, 00198 Rome, Italy; [email protected] * Correspondence: [email protected]; Tel.: +39-051-209-1235 † These authors contributed equally to this work. Received: 3 July 2018; Accepted: 1 August 2018; Published: 8 August 2018 Abstract: Neurodegenerative diseases represent a heterogeneous group of disorders that share common features like abnormal protein aggregation, perturbed Ca2+ homeostasis, excitotoxicity, impairment of mitochondrial functions, apoptosis, inflammation, and oxidative stress.
    [Show full text]
  • Burkitt Lymphoma
    NON-HODGKIN LYMPHOMA TREATMENT REGIMENS: Burkitt Lymphoma (Part 1 of 3) Clinical Trials: The National Comprehensive Cancer Network recommends cancer patient participation in clinical trials as the gold standard for treatment. Cancer therapy selection, dosing, administration, and the management of related adverse events can be a complex process that should be handled by an experienced health care team. Clinicians must choose and verify treatment options based on the individual patient; drug dose modifications and supportive care interventions should be administered accordingly. The cancer treatment regimens below may include both U.S. Food and Drug Administration-approved and unapproved indications/regimens. These regimens are provided only to supplement the latest treatment strategies. These Guidelines are a work in progress that may be refined as often as new significant data become available. The NCCN Guidelines® are a consensus statement of its authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult any NCCN Guidelines® is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient’s care or treatment. The NCCN makes no warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any way. Induction Therapy—Low Risk Combination Regimens1,a Note: All recommendations are Category 2A unless otherwise indicated. REGIMEN DOSING CODOX-M
    [Show full text]
  • Weak Interaction of the Antimetabolite Drug Methotrexate with a Cavitand Derivative
    International Journal of Molecular Sciences Article Weak Interaction of the Antimetabolite Drug Methotrexate with a Cavitand Derivative Zsolt Preisz 1,2, Zoltán Nagymihály 3,4, Beáta Lemli 1,4 ,László Kollár 3,4 and Sándor Kunsági-Máté 1,2,4,* 1 Institute of Organic and Medicinal Chemistry, Medical School, University of Pécs, Szigeti 12, H-7624 Pécs, Hungary; [email protected] (Z.P.); [email protected] (B.L.) 2 Department of General and Physical Chemistry, Faculty of Sciences, University of Pécs, Ifjúság 6, H 7624 Pécs, Hungary 3 Department of Inorganic Chemistry, Faculty of Sciences, University of Pécs, Ifjúság 6, H 7624 Pécs, Hungary; [email protected] (Z.N.); [email protected] (L.K.) 4 János Szentágothai Research Center, University of Pécs, Ifjúság 20, H-7624 Pécs, Hungary * Correspondence: [email protected]; Tel.: +36-72-503600 (ext. 35449) Received: 2 June 2020; Accepted: 16 June 2020; Published: 18 June 2020 Abstract: Formation of inclusion complexes involving a cavitand derivative (as host) and an antimetabolite drug, methotrexate (as guest) was investigated by photoluminescence measurements in dimethyl sulfoxide solvent. Molecular modeling performed in gas phase reflects that, due to the structural reasons, the cavitand can include the methotrexate in two forms: either by its opened structure with free androsta-4-en-3-one-17α-ethinyl arms or by the closed form when all the androsta-4-en-3-one-17α-ethinyl arms play role in the complex formation. Experiments reflect enthalpy driven complex formation in higher temperature range while at lower temperature the complexes are stabilized by the entropy gain.
    [Show full text]